Determination of breast cancer response to bevacizumab therapy using contrast-enhanced ultrasound and artificial neural networks

Journal of Ultrasound in Medicine

Volumn 29, Issue 4, 2010, Pages 577-585

  Hoyt, Kenneth ^a   Warram, Jason M ^a   Umphrey, Heidi ^a   Belt, Lin ^a   Lockhart, Mark E ^a   Robbin, Michelle L ^a   Zinn, Kurt R ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Bevacizumab; Breast cancer; Contrast agent; Neural networks; Ultrasound

Indexed keywords

ANIMALS; CLASSIFICATION (OF INFORMATION); DEEP NEURAL NETWORKS; DISEASES; IMAGE SEGMENTATION; NEURAL NETWORKS; TUMORS; ULTRASONICS;

BEVACIZUMAB; BREAST CANCER; CONTRAST AGENT; CONTRAST ENHANCED ULTRASOUND; CUSTOMIZED SOFTWARE; TIME-INTENSITY CURVES; ULTRASOUND CONTRAST AGENT; ULTRASOUND SCANNERS;

MEDICAL IMAGING;

BEVACIZUMAB; CONTRAST MEDIUM; FLUOROCARBON; MONOCLONAL ANTIBODY; PERFLUTREN;

ANIMAL; ARTICLE; ARTIFICIAL NEURAL NETWORK; ECHOGRAPHY; ECHOMAMMOGRAPHY; ENDOSCOPIC ECHOGRAPHY; EXPERIMENTAL NEOPLASM; FEMALE; MOUSE; NUDE MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; CONTRAST MEDIA; FEMALE; FLUOROCARBONS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, NUDE; NEURAL NETWORKS (COMPUTER); ULTRASONOGRAPHY, INTERVENTIONAL; ULTRASONOGRAPHY, MAMMARY;

EID: 77951462041     PISSN: 02784297     EISSN: None     Source Type: Journal    
DOI: 10.7863/jum.2010.29.4.577     Document Type: Article

References (30)

1. Relf M, LeJeune S, Scott PAE, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor â- 1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57:963-969.
2. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358: 2039-2049.
3. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res 1986; 46:467-473.
4. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7:987-989.
5. Jain RK. Determinants of tumor blow flow: a review. Cancer Res 1988; 48:2641-2658.
6. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-2676.
7. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64:3731-3736.
8. Dickson PV, Hamner JB, Sims TL, et al. Bevacizumabinduced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007; 13:3942-3945.
9. Bergsland E, Dickler MN. Maximizing the potential of bevacizumab in cancer treatment. Oncologist 2004; 9:36-42.
10. Chen HX. Expanding the clinical development of bevacizumab. Oncologist 2004; 9:27-35.
11. Rugo HS. Bevacizumab in the treatment of breast cancer: rationale and current data. Oncologist 2004; 9:43-49.
12. Cameron D, Bell R. Future use of bevacizumab and other anti-angiogenic agents in breast cancer. Eur J Cancer 2008; 6:40-50.
13. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006; 28:1779-1802.
14. Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endothelial growth factor: targeted therapy. Clin Cancer Res 2008; 14:6371-6375.
15. de Jong N, Frinkling P, ten Cate F, van der Wouw P. Characteristics of contrast agents and 2D imaging. IEEE Ultrasonics Symp 1996; 1:1449-1458.
16. Kim AY, Choi BI, Kim TK, Kim KW, Lee JY, Han JK. Comparison of contrast-enhanced fundamental imaging, second-harmonic imaging, and pulse-inversion harmonic imaging. Invest Radiol 2001; 36:582-588.
17. Eckersley RJ, Chin CT, Burns PN. Optimising phase and amplitude modulation schemes for imaging microbubble contrast agents at low acoustic power. Ultrasound Med Biol 2005; 31:213-219.
18. Shi WT, Forsberg F, Vaidyanathan P, Tornes A, Ostensen J, Goldberg BB. The influence of acoustic transmit parameters on the destruction of contrast microbubbles in vitro. Phys Med Biol 2006; 51:4031-4045.
19. Yeh CK, Su SY. Effects of acoustic insonation parameters on ultrasound contrast agent destruction. Ultrasound Med Biol 2008; 34:1281-1291.
20. Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM, Kaul S. Quantification of myocardial blood flow with ultrasound- induced destruction of microbubbles administeredas a constant venous infusion. Circulation 1998; 97:473-483.
21. Hoyt K, Warram JM, Umphrey H, et al. Assessing breast cancer response to bevacizumab using contrast-enhanced ultrasound: initial results using a murine model. IEEE Ultrasonics Symp. In press.
22. Floyd CE, Lo JY, Yun AJ, Sullivan DC, Kornguth PJ. Prediction of breast cancer malignancy using an artificial neural network. Cancer 1994; 74:2944-2948.
23. Joo S, Yang TS, Moon WK, Kim HC. Computer-aided diagnosis of solid breast nodules: use of an artificial neural network based on multiple sonographic features. IEEE Trans Med Imaging 2004; 23:1292-1300.
24. Djavan B, Remzi M, Zlotta A, Zeitz C, Snow P, Marberger M. Novel artificial neural network for early detection of prostate cancer. J Clin Oncol 2002; 20:921-929.
25. Chomas JE, Pollard RE, Sadlowski AR, et al. Contrastenhanced US of microcirculation of superficially implanted tumors in rats. Radiology 2003; 229:439-446.
26. Wang D, Stockard CR, Harkins L, et al. Immuno - histochemistry for the evaluation of angiogenesis in tumor xenografts. Biotech Histochem 2008; 83:179-189.
27. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 1991; 324:1-8.
28. Ladak HM, Mao F, Wang Y, et al. Prostate boundary segmentation from 2D ultrasound images. Med Phys 2000; 27:1777-1788. (Pubitemid 30666353)
29. Selvakumaran M, Yao KS, Feldman MD, O'Dwyer PJ. Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxiainduced apoptosis. Biochem Pharmacol 2008; 75:627-638.
30. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004; 165:35-52.